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In this article we review recent advances made in the
pathophysiology, diagnosis, and treatment of inhalation
injury. Historically, the diagnosis of inhalation injury
has relied on nonspecific clinical exam findings and
bronchoscopic evidence. The development of a
grading system and the use of modalities such as
chest computed tomography may allow for a more
nuanced evaluation of inhalation injury and enhanced
ability to prognosticate. Supportive respiratory care
remains essential in managing inhalation injury.
Adjuncts still lacking definitive evidence of efficacy
include bronchodilators, mucolytic agents, inhaled
anticoagulants, nonconventional ventilator modes,
prone positioning, and extracorporeal membrane
oxygenation. Recent research focusing on molecular
mechanisms involved in inhalation injury has increased
the number of potential therapies.thermal injury to the lungs [9]. The degree of inhalation
injury is variable and is dependent on several factors: theIntroduction
Despite important advances in the care of patients with
inhalation injury, which continues to be largely support-
ive, morbidity and mortality remain high [1]. Inhalation
injury can feature supraglottic thermal injury, chemical
irritation of the respiratory tract, systemic toxicity due
to agents such as carbon monoxide (CO) and cyanide,
or a combination of these insults. The resultant inflam-
matory response may cause higher fluid resuscitation
volumes, progressive pulmonary dysfunction, prolonged
ventilator days, increased risk of pneumonia, and acute
respiratory distress syndrome (ARDS) [2, 3].
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tions, current treatment options, and future avenues of
research.Pathophysiology
Inhalation injury complicates burns in approximately 10
to 20 % of patients and significantly increases morbidity
and mortality [2–5]. Other factors associated with a
significant effect on mortality include burn size and age
[6, 7] and the incidence of inhalation injury is correlated
with an increase in both these factors [6, 7]. Inhalation
injury has also been found to be an independent predictor
of mortality in burn patients [8] and worsens survival even
among patients with similar age and burn size [8]. Ther-
mal airway injury is generally limited to supraglottic struc-
tures, whereas injury to the lower airway is chemical in
nature. In the setting of steam, however, the injury is per-
vasive, causing damage to both upper airways and direct
gas components inhaled, the presence of particulate mat-
ter (soot), the magnitude of the exposure, and individual
host factors such as underlying lung disease and inability
to flee the incident.
Historically, it was speculated that the combustion of
certain materials, such as noncommercial polyurethane
foam, resulted in the formation of a neurotoxin [10];
however, newer material testing methods revealed most
smoke toxicity can be explained by a small number of
toxic gases exerting their effects through asphyxiation,
systemic toxicity, or direct effects on respiratory tissue
[11]. Many products of combustion, such as carbon
dioxide, function as simple asphyxiants by displacing
oxygen at the alveolar level. This is further exacerbated
by the hypoxic fire environment. CO functions systemic-
ally as an asphyxiant by (1) competitively displacing
oxygen from hemoglobin and (2) binding to cytochrome
oxidase at the mitochondrial level. By contrast, hydrogen
cyanide binds only to cytochrome oxidase [1].is distributed under the terms of the Creative Commons Attribution 4.0
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formaldehyde, and unsaturated aldehydes (for example,
acrolein), function as respiratory irritants. The chemical
irritation causes denuding of the respiratory mucosa,
leading to sloughing within the airways, and induces the
host inflammatory response. Furthermore, the chemical
injury stimulates vasomotor and sensory nerve endings
to produce neuropeptides. Preclinical studies have shown
these neuropeptides can induce an inflammatory response
[12]. Substance P and calcitonin gene-related peptide are
two suggested neuropeptides inducing tissue injury after
inhalation injury [12, 13]. Lange et al. [13] found an-
tagonists to calcitonin gene-related peptide and sub-
stance P attenuated the fluid shifts/inflammation in
an ovine model subjected to smoke and inhalation in-
jury. These neuropeptides then induce bronchocon-
striction and nitric oxide synthase (NOS) to generate
reactive oxygen species (ROS) [14]. As described by
Kraneveld and Nijkamp [14], these neuropeptides can
function as tachykinins, inducing a robust inflammatory
response with the downstream effects of bronchoconstric-
tion, increased vascular permeability, and vasodilation.
Furthermore, tachykinins like substance P and neurokinin
A can modulate immune cells and stimulate neutrophil
and eosinophil chemotaxis [14].
Overall, these factors potentiate local cellular damage
and the loss of hypoxic pulmonary vasoconstriction. The
loss of hypoxic pulmonary vasoconstriction causes bron-
chial blood flow to increase by a factor of 10 within
20 min of inhalation injury. ROS may also induce mito-
chondrial dysfunction and cellular apoptosis [15]. Tissue
factor expressed by damaged respiratory epithelial cells
and alveolar macrophages initiates the extrinsic coagula-
tion cascade, disrupting pro- and anti-coagulant alveolar
homeostasis. We found, for example, that smoke inhal-
ation injury contributes to a hypercoagulable state in the
lung by inducing plasminogen activator inhibitor 1 and
stabilizing its mRNA [16].
In addition, the increased bronchial blood flow delivers
activated polymorphonuclear leukocytes and cytokines
to the lung, potentiating the host inflammatory response.
The loss of an intact bronchial epithelium and the ef-
fects of ROS result in a loss of plasma proteins and fluid
from the intravascular space into the alveoli and bron-
chioles [17]. The transvascular shift of protein causes ex-
udate and cast formation within the airways, leading to
alveolar collapse or complete occlusion of the airways
[17]. Experimental measures to decrease bronchial blood
flow show attenuation of airway obstruction, pulmonary
edema, and improved oxygenation [18]. These processes -
loss of hypoxic vasoconstriction, increased blood flow to
injured lung segments, decreased ventilation of collapsed
segments - contribute to ventilation-perfusion mismatch
as a primary mechanism of hypoxemia following thesmoke inhalation injury [19]. Atelectasis, dysfunction of
the immune system, and mechanical ventilation, in turn,
predispose to pneumonia as a common complication of
inhalation injury.
Many studies are now being completed to better
understand the role pro- and anti-inflammatory media-
tors, or other immune modulators, play in patient out-
comes. Albright et al. [1] demonstrated a graded increase
in inflammatory cytokines from bronchoalveolar lavage
fluid (IL-4, IL-6, IL-9, IL-15, interferon-gamma, granulo-
cyte macrophage colony-stimulating factor, monocyte
chemoattractant protein-1) that correlates with the sever-
ity of inhalation injury noted on bronchoscopic evaluation
(grades 3 or 4 versus 1 or 2). They also found a significant
shift from a macrophage-predominant population of cells
in lavage fluid to one dominated by neutrophils [1]. This
is thought to contribute to the later immune dysfunction,
bacterial overgrowth, and pneumonia [1]. The source of
the cytokines identified in inhalation is thought to be
secondary to complement activation by heat denatured
proteins [20]. The stimulation of the complement cascade
releases histamine, resulting in xanthine oxidase upregula-
tion and ROS formation [20, 21].
Davis et al. [22] showed several plasma immune medi-
ators were associated with increased inhalation injury
severity, even after adjusting for age and percentage of
total body surface area burned. IL-1 receptor antagonist
(IL-1RA), an anti-inflammatory immune mediator, had
the strongest correlation with injury severity and out-
come measures, including mortality [22]. The authors
also found a much lower IL-1β to IL-1RA ratio in pa-
tients with inhalation injury who died. Given that IL-1β
is an essential component of the host defense, they
hypothesized that insufficient IL-1β or excessive IL-1RA
results in systemic immune dysfunction.
The formation of ROS, such as superoxide anions
(O2
−), hydrogen peroxide (H2O2), and hydroxyl radicals
(OH−; the most unstable and reactive), appears to play a
major role in numerous injury models [23]. Under normal
circumstances the body has compensatory antioxidant
mechanisms to mitigate the effects of ROS. Following re-
perfusion or injury, however, there is a large burst of ROS,
which overwhelm the body’s protective measures. As a re-
sult, the ROS can lead to cell injury through neutrophil at-
traction and cytokine production. Indeed, evidence of
oxidative stress is found in plasma and lung tissue follow-
ing smoke inhalation injury [24]. IL-8, a potent chemo-
kine, has been suggested to play a vital role in the
initiation and progression of lung inflammation after
smoke inhalation [25]. NOS-dependent formation of ROS
has been studied in inhalation injury. Activated neutro-
phils produce large quantities of superoxide that combine
with nitric oxide to produce peroxynitrite, which can
damage DNA [20]. Peroxynitrite and the resultant DNA
Fig. 1 Fiberoptic bronchoscopy of patient on post-burn day 0
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(PARP-1), a nuclear repair enzyme and coactivator of
NF-ĸB, which can deplete ATP and produce cell
damage [26, 27]. Combined, these factors contribute
to an increase in IL-8 [27], induce NOS, neutrophil
chemotaxis, and increase ROS production [20]. For
this reason, heparin/acetylcysteine combinations are being
utilized as ROS scavengers in inhalation injury [20].
Diagnosis
Classically, the diagnosis of inhalation injury was sub-
jective and made on the basis of clinical findings. When
evaluating a patient with suspected inhalation injury, a
clinician first reviews the history and reported mechan-
ism to determine the likelihood of an inhalation injury.
Pertinent information includes exposure to flame,
smoke, or chemicals (industrial and household), duration
of exposure, exposure in an enclosed space, and loss of
consciousness or disability. Pertinent physical exam find-
ings include facial burns, singed facial or nasal hair, soot
or carbonaceous material on the face or in the sputum,
and signs of airway obstruction including stridor, edema,
or mucosal damage [3]. Older patients, and those with
more extensive burns, are at increased risk of inhalation
injury because of prolonged exposure to the fire envir-
onment [8].
There are several modalities for confirming inhalation
injury to include fiberoptic bronchoscopy (FOB), chest
computed tomography (CT), carboxyhemoglobin meas-
urement, radionuclide imaging with 133Xenon, and pul-
monary function testing. Many of these modalities lack
sensitivity, are invasive, or are subject to significant vari-
ability between institutions. In studies by Shirani et al.
[8], the following gradation of morbidity and mortality
risk was seen in order of increasing risk: (1) patients
without inhalation injury; (2) patients with inhalation in-
jury by 133Xenon scan only, but not by FOB; and (3) pa-
tients with inhalation injury by FOB. Also, presence of
inhalation injury on FOB predicted risk of acute lung in-
jury and the need for increased fluid resuscitation vol-
umes. More recent studies have found a significant
correlation between the severity of inhalation injury on
FOB and mortality [28].
There are several difficulties in diagnosing the pres-
ence and severity of inhalation injuries. Although several
laboratories have developed dose–response models of in-
halation injury in large animals [29], the characteristics
of the material inhaled are important in determining the
degree of respiratory failure. In addition, differences in
the individual host inflammatory response may lead to a
heterogeneous clinical presentation [30]. FOB is unable
to assess distal airways and respiratory bronchioles;
therefore, damage to this portion of the lung has been
proposed as an explanation for the discordance betweenbronchoscopic severity of injury and mortality. Despite
these limitations, FOB continues to be the standard
technique used to assess the presence and severity of in-
halation injury. Its relative ease and availability allows
the initial diagnosis to be made (Fig. 1), and allows the
inhalation injury to be followed serially (Figs. 2 and 3).
Given the lack of a widely standardized and validated
method for scoring inhalation injury severity, Woodson
[30] has proposed a large multicenter study to create
such a scoring system to allow for more reliable prog-
nostic estimations. To date, no such study has been
done, though one is currently underway based on clin-
ical, radiographic, bronchoscopic, and biochemical pa-
rameters (ClinicalTrials.gov identifier NCT01194024).
Multiple studies have demonstrated that inhalation in-
jury is a graded phenomenon with severity correlating
with outcome. The Abbreviated Injury Score grading
scale for inhalation injury on bronchoscopy has been
shown to correlate with an increase in mortality as well
impaired gas exchange [1, 28, 31]. This scale is shown in
Table 1. Endorf and Gamelli [3] found that patients with
more severe inhalation injury on initial bronchoscopy
(grades 2, 3, 4) had worse survival rates than patients
with lower scores (grades 0 or 1) (P = 0.03). They also
noted the highest-grade inhalation injuries were not ne-
cessarily associated with an increased fluid requirement,
contrary to prior data. Lastly, they found patients with
an arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) ratio <350 upon presentation had a
statistically significant increase in fluid resuscitation needs
compared with patients with a ratio >350 (P = 0.03) [3].
Ryan et al. [32] have stated that, at this time, the most
Fig. 2 Fiberoptic bronchoscopy of patient on post-burn day 4
Table 1 Abbreviated Injury Score grading scale for inhalation
injury on bronchoscopy [1]
Grade Class Description
0 No injury Absence of carbonaceous deposits, erythema,
edema, bronchorrhea, or obstruction
1 Mild injury Minor or patchy areas of erythema, carbonaceous
deposits, bronchorrhea, or bronchial obstruction
2 Moderate injury Moderate degree of erythema, carbonaceous
deposits, bronchorrhea, or bronchial obstruction
3 Severe injury Severe inflammation with friability, copious
carbonaceous deposits, bronchorrhea, or
obstruction
4 Massive injury Evidence of mucosal sloughing, necrosis,
endoluminal obstruction
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PaO2/FiO2 ratio after the resuscitation has started. This is
based on a retrospective review by Hassan et al. [28] of
105 patients admitted with inhalation injury. They
assessed respiratory function by using the PaO2/FiO2 ratio
from 0 to 192 h after injury. Their study showed a signifi-
cant difference (P < 0.01) in PaO2/FiO2 ratios between pa-
tients who died (mean PaO2/FiO2 ratio 20.17) and those
who survived (mean PaO2/FiO2 ratio 32.24). Ultimately,
they propose to use PaO2/FiO2 ratio as a predictor of sur-
vival once the initial burn resuscitation has been com-
pleted and a full response to injury is able to be mountedFig. 3 Fiberoptic bronchoscopy of patient on post-burn day 10[28]. Similarly, Cancio et al. [33] found that the mean
alveolar-arterial oxygen gradient during the first 2 days
was an independent predictor of mortality in mechanically
ventilated burn patients. It is important to note that PaO2/
FiO2 can be arbitrarily high or low depending on the
choice of ventilator mode. In addition, PaO2/FiO2 may be
affected by the volume of resuscitation. Therefore, we do
not use PaO2/FiO2 as a basis for diagnosis of inhalation in-
jury, but use it to trend the patient’s oxygenation and po-
tential need for nonconventional ventilation.
Other means of evaluating the severity of inhalation
injury include chest CT. First, a scoring system for se-
verity of CT scan findings has been developed [29]. Our
group studied 25 patients with inhalation injury and 19
patients without inhalation injury who received a chest
CT within 24 h of admission [34]. The severity of radio-
graphic findings was calculated by looking at 1-cm axial
slices from the chest CT and these were scored by
adding the highest radiologist’s score (RADS) for each
quadrant. The RADS scoring system is shown in Table 2,
and the various RADS findings are shown in Fig. 4. Our
group assessed a composite endpoint of pneumonia,
acute lung injury/ARDS, and death. We found that the
detection of inhalation injury on bronchoscopy was
associated with an 8.3-fold increase in the composite
endpoint. A high RADS score (>8 per slice) in addition to
a positive bronchoscopy was associated with a 12.7-fold
increase, thus showing the potential for chest CT to com-
plement bronchoscopy in detecting clinically significant




Increased interstitial markings 1
Ground glass opacification 2
Consolidation 3
Fig. 4 Example of radiologist’s score findings in chest computed tomography scan slice [34]
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measure bronchial wall thickness 2 cm distal to the
tracheal bifurcation in patients who had sustained an in-
halation injury. The authors noted a statistically signifi-
cant correlation between bronchial wall thickness and
the development of pneumonia, total number of ventila-
tor days, and ICU length of stay. They also found that a
bronchial wall thickness value of >3.0 mm predicted the
development of pneumonia with a sensitivity of 79 %
and specificity of 96 %. Interestingly, this study was not
able to replicate the association between Abbreviated In-
jury Score bronchoscopic scoring and clinical outcomes
as described above [35].
A third approach to using the CT scan is virtual bron-
choscopy. A three-dimensional reconstructed image is
presented in such a way that the viewer navigates
through the lung as if using a bronchoscope. We found
that virtual bronchoscopy agrees best with FOB in the
detection of airway narrowing, and less so in the detec-
tion of blistering or necrosis [36].
Problems with using chest CT as part of a diagnostic
algorithm for inhalation injury include determining the
optimal timing of the test and how to interpret abnor-
mal radiographic findings in the setting of a negative
bronchoscopy. Putman et al. [37] found that chest radi-
ography on admission was rarely helpful in determining
the presence or severity of inhalation injury, but its use
is helpful as a baseline for determining future changes.
Respiratory support
Given the limited availability of targeted therapies for
inhalation injury, one of the fundamental tenets is
supportive respiratory care. This includes aggressive pul-
monary toilet and mechanical ventilation when indi-
cated. It should be noted that approximately 20 to 33 %of patients hospitalized with inhalation injury experience
some degree of upper airway obstruction due to
pharyngeal edema that can progress rapidly [38]. As
thermal injury increases airway edema and can lead
to airway obstruction, early intubation is favored [4].
This is of particular concern in patients who receive
large amounts of intravenous fluids during resuscitation.
Generally speaking, the most experienced clinician in air-
way management should perform endotracheal intubation
with the largest available, age-appropriate endotracheal
tube for patients with suspected or impending upper air-
way obstruction in the setting of inhalation injury. One
study suggests prophylactic intubation can decrease mor-
tality related to pulmonary-related death in patients with
inhalation injury [39].
Maintaining bronchial hygiene is paramount in patients
who have suffered inhalation injury. Early ambulation,
chest physiotherapy, airway suctioning, and therapeutic
bronchoscopy are adjunctive tools [38]. Reper et al. [40]
demonstrated that intrapulmonary percussive ventilation
administered through a face mask to spontaneously
breathing patients with smoke inhalation injury, hypoxia,
and persistent atelectasis can result in a significant im-
provement in PaO2/FiO2 ratio.
A low threshold should be maintained for intubation
and mechanical ventilation in inhalation injury due to
the progressive nature of the airway edema. Interest-
ingly, a study by Mackie et al. [41] showed an increased
use of mechanical ventilation in patients at a Dutch burn
center from 1997 to 2006 (76 %) compared with 1987 to
1996 (38 %) despite a decrease in the incidence of inhal-
ation injury (34 % versus 27 %). The authors hypothe-
sized that this was related to the institution of Advanced
Trauma Life Support principles in the mid-1990s in the
Netherlands. Mackie [42] also suggested mechanical
Fig. 5 Comparison of the PaO2/FiO2 ratio over time between high
frequency percussive ventilation (HFPV) and low-tidal volume
ventilation (LTV) (asterisks denote P < 0.05) [49]
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in burn patients independent of inhalation injury. He
proposed increased intrathoracic pressure from positive
pressure ventilation led to decreased venous return,
followed by decreased cardiac and urine output. The
typical clinical reaction is to increase intravenous fluid
administration, resulting in higher volumes of infused
fluid, a known risk factor for adverse outcomes in burn
patients [42].
Multiple challenges, to include concern for ventilator-
induced lung injury in patients with inhalation injury,
have led to the use of unconventional ventilator
modes [43].
Conventional mechanical ventilation is limited in the
patient with inhalation injury. In a patient with fibrin
casts, extensive chest wall thermal injuries, or high
volumes of resuscitative fluid maintaining the recom-
mended tidal volumes of less than 7 ml/kg body weight
and plateau pressures of less than 30 cm water [44], can
prove difficult with conventional techniques. Therefore,
in order to apply lung-protective ventilation in patients
with inhalation injury, nonconventional ventilator modes
are employed.
High-frequency percussive ventilation (HFPV) was
first described in patients with inhalation injury as a
means of assisting with clearance of sloughed respiratory
mucosa and plugs, as well as decreasing iatrogenic baro-
trauma and the incidence of pulmonary infection [45].
Further studies have demonstrated benefits from using
HFPV prophylactically (that is, not as a salvage mode) in
both adult [46, 47] and pediatric populations [48]. Our
group performed a randomized controlled trial to com-
pare HFPV versus conventional low tidal volume (LTV)
ventilation [49]. While we detected no difference in
ventilator-free days between patients randomized to
HFPV compared with LTV ventilation, there was a sta-
tistically significant increase in the PaO2/FiO2 ratio for
the HFPV cohort on days 0 to 3 (Fig. 5). We also found
that less patients in the HFPV cohort required conver-
sion to a rescue mode of ventilation compared with the
LTV ventilation cohort [49]. Also, HFPV was associated
with a decrease in the incidence of pneumonia from 45
to 26 % (P < 0.005) and resulted in an improvement in
survival [46]. Although HFPV cannot reverse the effects
of inhalation injury, it can improve the clearance of
secretions, provide positive pressure throughout the
ventilator cycle, allow for lower airway pressures, and in-
crease functional reserve capacity [46].
Interestingly, a recent retrospective study by Sousse
et al. [50] compared high tidal volume (HTV) ventilation
(15 ± 3 ml/kg, n = 190) with LTV ventilation (9 ± 3 ml/kg,
n = 501) in pediatric patients suffering from inhalation
injury. Patients on HTV had fewer days on the venti-
lator (P < 0.005), increased maximum peak inspiratorypressure (P < 0.02), and plateau pressures (P < 0.02)
compared with those on LTV ventilation. Furthermore,
the incidence of atelectasis and ARDs was significantly
lower in the cohort receiving HTV ventilation (P < 0.0001
and P < 0.02, respectively). However, the HTV ventilation
group were not without complications and had a signifi-
cantly higher rate of pneumothorax compared with the
LTV ventilation group (P < 0.03). For pediatric patients
suffering from inhalation injury, HTV ventilation may be
better than traditional LTV ventilation [50]. The mecha-
nisms for this observation are unclear, but this study,
much like the previous study, suggests that we must be
cautious when extrapolating LTV ventilation to all patient
populations, especially in those with different pathophysi-
ologies. A randomized controlled trial may be necessary
to tease out the true impact of these divergent strategies.
Our group also looked at airway pressure release ventila-
tion (APRV) in a prospective animal model study. We
found that PaO2/FiO2 ratios were initially lower in pigs
with inhalation injury on APRV compared with conven-
tional mechanical ventilation, although this equilibrated at
48 h. Higher mean airway pressures were necessary to
maintain oxygenation in APRV, and, in the end, no sur-
vival difference was seen between APRV and conventional
mechanical ventilation [51].
Other nonventilator adjuncts to consider for inhal-
ation injury include prone positioning and extracorpor-
eal membrane oxygenation (ECMO). Our group showed
that prone positioning led to a statistically significant in-
crease in PaO2/FiO2 ratio in patients with inhalation in-
jury and refractory ARDS whose initial ratio was an
average of 87 ± 38 [52].
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ECMO in inhalation injury was limited by number of
studies and total patients available. There was a ten-
dency towards increased survival in burn patients with
acute hypoxemic respiratory failure treated with ECMO.
ECMO use of <200 h was correlated with higher survival
compared with time >200 h. There was no improvement
in survival if ECMO was initiated once the PaO2/FiO2
ratio was <60 [53].
Targeted therapies
Bronchodilators
Bronchodilators have been used in inhalation injury to
decrease airflow resistance and improve dynamic com-
pliance. β2-adrenergic agonists such as albuterol and sal-
butamol have been studied in both sheep and humans.
Ovine studies of smoke inhalation injury have shown
that both nebulized epinephrine and albuterol decrease
airway pressure by smooth muscle relaxation and in-
crease PaO2/FiO2 ratio [54, 55] by limiting the degree of
bronchospasm. In addition, epinephrine decreases blood
flow to injured/obstructed airways, thus improving V/Q
matching.
Muscarinic receptor antagonists such as tiotropium
have been studied as well. The parasympathetic re-
sponse, mediated via muscarinic receptors in the lung,
causes smooth muscle constriction within the airways,
release of cytokines, and stimulation of submucosal
glands [2]. Therefore, by inhibiting these effects, airway
pressures are decreased and mucus secretion and cyto-
kine expression are reduced [56]. Jonkam et al. demon-
strated in an ovine model that tiotropium improved
PaO2/FiO2 ratios and decreased peak airway pressures in
the first 24 h following inhalation injury [56].
There is also evidence that both beta agonists and
muscarinic receptor antagonists may decrease the host
inflammatory response. Additionally, both muscarinic
and adrenergic receptors are found on respiratory epi-
thelial gland cells and may impact regeneration and
healing following injury. Jacob et al. [57] showed in
an ovine model that albuterol/tiotropium resulted in
an increase in bronchial ciliated duct and submucosal
gland cell proliferation following smoke inhalation
and burn injury. In healthy human volunteer and
animal studies, epinephrine has been shown to de-
crease tumor necrosis factor-alpha levels and potentiate
IL-10 (a cytokine inhibitor) after lipopolysaccharide stimu-
lation [58, 59].
Mucolytic agents
N-acetylcysteine (NAC) is a powerful mucolytic and may
have a role in mitigating ROS damage as it is a precursor
of glutathione and a strong reducing agent. While it may
aid in breaking up thick airway secretions, it is also anairway irritant and may produce bronchoconstriction;
therefore, patients are frequently pre-dosed with a
bronchodilating agent [38]. NAC has been proven to be
effective in combination with aerosolized heparin for the
treatment of inhalation injury in animal studies [60].
Anticoagulants
Inhaled anticoagulants have been used to ameliorate the
formation of fibrin casts, which contribute to airway ob-
struction following inhalation injury. This became a
prevalent treatment after Desai et al. [61] demonstrated
its utility in a pediatric inhalation injury population.
However, in a subsequent retrospective review by Holt
et al. [62], a cohort of 150 patients with inhalation injury
showed no significant improvement in clinical outcomes
in patients treated with inhaled heparin and acetylcys-
teine. This retrospective study allowed for the institution
of nebulized heparin every 4 h for up to 7 days at the at-
tending physician's discretion, and it is unclear whether
significant selection bias impacted results [62]. There
has been at least one case report of coagulopathy in a
patient receiving nebulized heparin and acetylcysteine
for inhalation injury [63]. However, Yip et al. [64] dem-
onstrated that nebulized heparin does not increase the
risk for pulmonary or systemic bleeding.
Miller et al. [65] found in a retrospective study that
patients with inhalation injury who received nebulized
heparin and NAC in addition to albuterol experienced a
survival benefit with a number needed to treat of 2.73. A
multi-center randomized controlled trial by Glas et al.
[66] is currently underway to assess nebulized heparin
versus placebo in inhalation injury.
Enkhbaatar et al. [67] used a combination of aerosolized
heparin and recombinant human antithrombin in an
ovine model of cutaneous burn and smoke inhalation.
They found the two agents resulted in better lung
compliance, less pulmonary edema, and less airway
obstruction than controls. Interestingly, neither agent
used alone had the same effect [67]. Using this same
injury model, they demonstrated that a fibrinolytic
agent, tissue plasminogen activator, decreased pul-
monary edema, airway obstruction and airway pres-
sures and improved gas exchange [68].
A systematic review of inhaled anticoagulants, includ-
ing heparin, heparinoids, antithrombin, and fibrinolytics,
in inhalation injury confirmed improved survival and de-
creased morbidity in preclinical and clinical studies [69].
Additionally, anticoagulants may have a systemic role in
mitigating host inflammatory response. Combined burn
and smoke inhalation injury is associated with myocar-
dial impairment similar to septic cardiomyopathy.
Rehberg et al. [70] demonstrated a decrease in the in-
flammatory changes underlying myocardial dysfunc-
tion and improvement in contractility in an ovine
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antithrombin.
Anti-inflammatory agents
More specific therapies to mitigate the host inflamma-
tory response and the positive feedback loop introduced
through neutrophil migration into the airway and pro-
duction of ROS and peroxynitrite (ONOO−) is an area
of intense interest [71]. Neutralization of peroxynitrite
with peroxynitrite decomposition catalysts has been
demonstrated to be cytoprotective and provide beneficial
effects in an ovine model of smoke inhalation injury.
Hamahata et al. [72] demonstrated that peroxynitrite de-
composition catalyst delivery into the bronchial artery of
sheep subjected to burns and inhalation injury attenu-
ated pulmonary damage when compared with a control
group that received saline. Additionally, in an animal
and human in vitro model of smoke inhalation injury,
Perng et al. [25] demonstrated that NOS-mediated acti-
vation of the host inflammatory response was attenuated
by inhibiting a specific signaling pathway (adenosine-
monophosphate-activated protein kinase).
Systemic toxicities
CO has an affinity for hemoglobin 200 to 250 times
greater than oxygen and exposure results in hypoxia and
ischemia. Unlike inhalation injury, CO has deleterious
effects at the level of hemoglobin and more specifically
the ability for oxygen delivery. CO acts to displace oxy-
gen from hemoglobin (forming carboxyhemoglobin
(COHb)) and binds to cytochrome c oxidase. COHb
shifts the oxygen dissociation curve to the left, ultimately
leading to decreased oxygen delivery at the tissue level
and interfering with cellular respiration at the mitochon-
drial level [73]. Symptoms of CO toxicity include confu-
sion, stupor, coma, seizures, and myocardial infarction
[74]. CO diagnosis requires the use of a Co-oximeter
(not available in every blood gas lab), since elevated
COHb levels may be present despite normal PaO2 and
oxygen saturation readings. Available since 2005, newer,
non-invasive CO-oximetry monitors permit more rapid
diagnosis [75]. CO poisoning is associated with an in-
creased risk of mortality even at long-term follow-up
(median of 7.6 years) [74]. Complications of CO poison-
ing include persistent and delayed neurologic sequelae
and myocardial injury, as well as functional effects on
leukocytes, platelets, and vascular endothelium [73].
Treatment of CO poisoning involves providing 100 %
oxygen, which shortens the half-life of COHb to about
45 min.
Hyperbaric oxygen therapy (HBO) has been used to
treat CO poisoning and can further reduce the COHb
half-life to about 20 min. The benefits of HBO were evi-
dent in a study of 75 patients with acute CO poisoning.Three treatment sessions were administered within 24 h
and neuropsychological tests were administered at vari-
ous points throughout the study. They found the rates
of cognitive sequelae were reduced at 6 weeks and
12 months after CO poisoning in patients with three
HBO sessions [76]. It should be pointed out that the
theoretical basis for HBO up to 24 h after exposure is to
facilitate the clearance of CO from cytochrome c oxidase
in the brain, rather than to increase its clearance from
hemoglobin in the blood. Logistical factors have limited
the utilization of HBO. A systematic review found that
not enough evidence exists at this point to determine
definitively whether HBO reduces adverse neurologic
outcomes after CO poisoning [77]. Continued advance-
ments in HBO technology combined with increased ICU
accessibility will likely result in the generation of more
clinical studies in this area.
The gaseous form of cyanide, hydrogen cyanide
(HCN), is formed in fire atmospheres from the thermal
decomposition of nitrogen-containing polymers, both
natural (wool, silk, and paper), and synthetic (nylon and
polyvinyl chloride). The significance of HCN in fire
environments is unclear [11]. The lack of a rapid and
reliable test to detect cyanide poisoning limits our
understanding of the role of HCN in inhalation injury
[78]. Additionally, symptoms can mimic CO poisoning.
Dumestre et al. [79] found that most burn centers do not
test for cyanide poisoning on admission and do not ad-
minister an antidote on the basis of clinical suspicion
alone. Lactate has been suggested as a marker for severity
of cyanide poisoning without other comorbidities [80], but
its role in inhalation injury is less clear in a population at
risk for CO poisoning and with coexisting hypovolemic
shock. Hydroxocobalamin, the most commonly available
antidote (sold as Cyanokit®), binds to HCN to form cyano-
cobalamin, which is nontoxic and excreted in the urine.
The standard dose of 5 g is infused intravenously over
15 min. A second dose of 5 g can be administered in pa-
tients with severe toxicity or poor clinical response. It is
generally regarded as safe. Red discoloration of the skin
and urine is common, which may interfere with colorimet-
ric assays.
Sodium nitrite (300 mg) and sodium thiosulfate (12.5 g)
are also commercially available (sold as Nithiodote™). Prior
to 2007, when hydroxocobalamin became available, so-
dium nitrite and sodium thiosulfate were used primarily
for cyanide poisoning despite limited data as to their effi-
cacy. In 2012, Bebarta et al. [81] evaluated sodium thiosul-
fate versus hydroxocobalamin in a swine model of severe
cyanide poisoning. They found that sodium thiosulfate
failed to reverse cyanide-induced cardiovascular collapse.
Further, sodium thiosulfate was not found to be effective
when added to hydroxocobalamin. Hydroxocobalamin
alone was found to be effective for severe cyanide toxicity.
Walker et al. Critical Care  (2015) 19:351 Page 9 of 12Treatment with nitrites carries significant risk of
hypotension and methemoglobinemia, which can further
jeopardize tissue oxygen delivery.
Complications from inhalation injuryInhalation injury
can be divided into anatomic levels and the mechanism
of injury - direct thermal injury to the upper airways or
chemical injury to the subglottic region and tracheo-
bronchial tree [82–84]. The associated complications
vary with the level of injury and are also effected by in-
tubation, infection, and chronic inflammation [82]. In
addition, the complications from injury may be acute or
delayed. Pneumonia and airway obstruction are early
complications of inhalation injury and have been well
described in the literature [4, 8]. However, there is a
paucity of data on the long-term or delayed complica-
tions from inhalation injury [84].
Pneumonia
The most common complication following inhalation in-
jury is respiratory tract infection [85]. Thermal injury ac-
tivates the host inflammatory response which, when
coupled with direct pulmonary injury, places the respira-
tory system at risk for infection. There is also evidence
inhalation injury damages ciliated cells and causes them
to detach from the airway epithelium [86]. Coupled with
the exfoliation of airway epithelium by chemical irrita-
tion, the loss of ciliated cells impairs pulmonary immune
function [85, 86]. Surfactant production is also impaired
[87] as is mucociliary transport secondary to damage to
airway epithelium [88]. The development of respiratory
tract infection is also effected by decreased function of
pulmonary macrophages [89]. Once the diagnosis of
pneumonia is made, empiric antibiotics should be imme-
diately administered. The antibiotic regimen should then
be tailored based on the final sputum culture.
At this institution, 1,058 burn patients were evaluated
with 35 % diagnosed with inhalation injury via bronchos-
copy or 133Xenon lung scan [8]. Of these patients, 38 %
developed pneumonia compared with 8.8 % in those
without inhalation injury. These authors reported an
estimated 20 % increase in mortality with burns and
concomitant inhalation injury; mortality increased to
60 % with the development of pneumonia. They found
inhalation injury and pneumonia to be independent risk
factors for mortality [8].
Airway obstruction
With direct injury to airway epithelium and fluid shifts,
upper airway obstruction and pulmonary edema can
occur [83]. Airway obstruction is further exacerbated by
large fluid resuscitations and should be avoided [83].
Approximately one-third to one-fifth of patients with in-
halation injury suffer from acute airway obstruction due
to injury to supraglottic structures [38]. These patientsrequire a secure airway either by intubation or tracheos-
tomy [90]. Musosal edema usually peaks around 24 h
post-burn and slowly improves over the following sev-
eral days [90, 91].
From intubation, certain acute complications are
known - barotrauma and suction-related injuries - which
place the patient more at risk for hospital-acquired
pneumonia [90]. Delayed consequences of intubation in-
clude tracheomalacia, subglottic stenosis, or innominate
fistula [38, 43, 90, 92]. Complications associated with
tracheostomies include bleeding, tube malposition, tra-
cheal ulcerations, and tracheitis [91].
Subglottic stenosis and other complications
Direct thermal injury below the vocal cords is unusual
given the heat dissipation that occurs in the upper airways
[93]. It is the particulate matter from the smoke inhalation
and inhalation of steam that contributes significantly to
the inflammatory cascade below the larynx [84, 91, 93, 94]
and the formation of scar tissue or polyps.
Endobronchial polyps have been reported as both
acute and delayed consequences of inhalation injury
[84]. The etiology of polyps has been attributed to the
epithelialization and fibrous replacement of granulation
tissue after damage to the mucosal surfaces. Prevalence is
unknown and development can be acute or delayed [84].
A retrospective review by Yang et al. [95] evaluated
the incidence of tracheal stenosis in 1,878 burn patients.
They found 0.36 % (seven patients) developed tracheal
stenosis with five of them having FOB-confirmed inhal-
ation injury (5.5 %). The average time to development
was 7 months post-burn. Six patients required intub-
ation for either respiratory distress or prophylaxis. They
found prolonged intubation, the presence of inhalation
injury, repeated intubates, and neck scar contractures
impacted the development of tracheal stenosis [95].
Given the delayed development of stenosis, patients are
at risk even after discharge and the true rate is unknown
as patients can be symptom free. Other studies report a
higher rate of tracheal stenosis in patients with inhal-
ation injury (24 % [96] and 53 % [97]), and predominates
in those who underwent intubation [98].
Other complications associated with inhalation injury
are bronchiectasis [82, 99, 100], bronchiolitis obliterans
[100], vocal cord fixation or fusion [82, 101], and dys-
phonia [102]. In order to identify and monitor the
development of these complications, long-term follow-up
(pulmonary function testing and FOB) is necessary
[82, 98].
Conclusion
Inhalation injury remains a significant cause of mor-
bidity and mortality in thermally injured patients. Treat-
ment of inhalation injury remains largely supportive.
Walker et al. Critical Care  (2015) 19:351 Page 10 of 12Recent research has led to substantial gains in the under-
standing of the molecular pathophysiology of inhalation
injury. These advances as well as preclinical studies
on targeted therapies provide hope for reversal of
specific mechanisms of morbidity and improvement
in outcomes.
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